CoChat

Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study

Open access
Carazo, Sara, Skowronski, Danuta M, Brisson, Marc, Barkati, Sapha, Sauvageau, Chantal, Brousseau, Nicholas, Gilca, Rodica, Fafard, Judith, Talbot, Denis, Ouakki, Manale, Gilca, Vladimir, Carignan, Alex, Deceuninck, Geneviève, De Wals, Philippe, De Serres, Gaston · 2023 · The Lancet Infectious Diseases

Published version of a preprint

Cited by 116

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Background There is a paucity of data on vaccine-induced or infection-induced (hybrid or natural) immunity against omicron (B.1.1.529) subvariant BA.2, particularly in comparing the effects of previous SARS-CoV-2 infection with the same or different genetic lineage. We aimed to estimate the protection against omicron BA.2 associated with previous primary infection with omicron BA.1 or pre-omicron SARS-CoV-2, among health-care workers with and without mRNA vaccination. Methods We conducted a test-negative case-control study among health-care workers aged 18 years or older who were tested for SARS-CoV-2 in Quebec, Canada, between March 27 and June 4, 2022, when BA.2 was the predominant variant and was presumptively diagnosed with a positive test result. We identified cases (positive test during study period) and controls (negative test during study period) using the provincial laboratory database that records all nucleic acid amplification testing for SARS-CoV-2 in Quebec, and used the provincial immunisation registry to determine vaccination status. Logistic regression models compared the likelihood of BA.2 infection or reinfection (second positive test ≥30 days after primary infection) among health-care workers who had previous primary infection and none to three mRNA vaccine doses versus unvaccinated health-care workers with no primary infection. Findings 258 007 SARS-CoV-2 tests were done during the study period. Among those with a valid result and that met the inclusion criteria, there were 37 732 presumed BA.2 cases (2521 [6·7%] reinfections following pre-omicron primary infection and 659 [1·7%] reinfections following BA.1 primary infection) and 73 507 controls (7360 [10·0%] had pre-omicron primary infection and 12 315 [16·8%] had BA.1 primary infection). Pre-omicron primary infection was associated with a 38% (95% CI 19–53) reduction in BA.2 infection risk, with higher BA.2 protection among those who had also received one (56%, 95% CI 47–63), two (69%, 64–73), or three (70%, 66–74) mRNA vaccine doses. Omicron BA.1 primary infection was associated with greater protection against BA.2 infection (risk reduction of 72%, 95% CI 65–78), and protection was increased further among those who had received two doses of mRNA vaccine (96%, 95–96), but was not improved with a third dose (96%, 95–97). Interpretation Health-care workers who had received two doses of mRNA vaccine and had previous BA.1 infection were subsequently well protected for a prolonged period against BA.2 reinfection, with a third vaccine dose conferring no improvement to that hybrid protection. If this protection also pertains to future variants, there might be limited benefit from additional vaccine doses for people with hybrid immunity, depending on timing and variant. Funding Ministère de la Santé et des Services Sociaux du Québec.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1473-3099(22)00578-3

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Research works printed but not linked: 16

  1. Andrews, 2022, Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant, N Engl J Med, 386, 1532, 10.1056/NEJMoa2119451 · doi:10.1056/nejmoa2119451 · Paper page
  2. Kirsebom, 2022, COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England, Lancet Infect Dis, 22, 931, 10.1016/S1473-3099(22)00309-7 · DOI · Paper page
  3. Stegger, 2022, Occurrence and significance of omicron BA.1 infection followed by BA.2 reinfection, medRxiv
  4. Nevejan, 2022, Early SARS-CoV-2 reinfections within 60 days highlight the need to consider antigenic variations together with duration of immunity in defining retesting policies, medRxiv
  5. Yahav, 2021, Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity, Clin Microbiol Infect, 27, 315, 10.1016/j.cmi.2020.11.028 · DOI · Paper page
  6. Cerqueira-Silva, 2022, Vaccination plus previous infection: protection during the omicron wave in Brazil, Lancet Infect Dis, 22, 945, 10.1016/S1473-3099(22)00288-2 · DOI
  7. Carazo, 2022, Protection against omicron re-infection conferred by prior heterologous SARS-CoV-2 infection, with and without mRNA vaccination, medRxiv
  8. Schnitzer, 2021, Identifiability and estimation under the test-negative design with population controls with the goal of identifying risk and preventive factors for SARS-CoV-2 infection, Epidemiology, 32, 690, 10.1097/EDE.0000000000001385 · DOI
  9. Leidi, 2022, Risk of reinfection after seroconversion to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a population-based propensity-score matched cohort study, Clin Infect Dis, 74, 622, 10.1093/cid/ciab495 · DOI
  10. Lu, 2021, Durability of SARS-CoV-2-specific T cell responses at 12-months post-infection, medRxiv
  11. Chin, 2022, Protection against omicron conferred by mRNA primary vaccine series, boosters, and prior infection, medRxiv
  12. Lind, 2022, Effectiveness of primary and booster COVID-19 mRNA vaccination against omicron variant SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection, medRxiv
  13. Yu, 2022, Neutralization of the SARS-CoV-2 omicron BA.1 and BA.2 variants, N Engl J Med, 386, 1579, 10.1056/NEJMc2201849 · DOI · Paper page
  14. Khan, 2022, Omicron sub-lineages BA.4/BA.5 escape BA.1 infection elicited neutralizing immunity, medRxiv
  15. Altarawneh, 2022, Protection of SARS-CoV-2 natural infection against reinfection with the omicron BA.4 or BA.5 subvariants, medRxiv
  16. Malato, 2022, Risk of BA.5 infection in individuals exposed to prior SARS-CoV-2 variants, medRxiv

Cited by

See all 116

Metadata

Authors
Carazo, S., Skowronski, D. M., Brisson, M., Barkati, S., Sauvageau, C., Brousseau, N., Gilca, R., Fafard, J., Talbot, D., Ouakki, M., Gilca, V., Carignan, A., Deceuninck, G., De Wals, P., & De Serres, G.
Venue
The Lancet Infectious Diseases
Publisher
Elsevier BV
Published
2023-01
Volume
23
Issue
1
Pages
45-55
ISSN
1473-3099 (ISSN-L)
OpenAlex
W4296577980
Cited by
116
References
21
FWCI
12.82
Type
journal article
Language
en
Open access
bronze
Funders
  • Ministère de la Santé et des Services sociaux
  • Institut National de Santé Publique du Québec

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study. https://app.cochat.ai/papers/10.1016/s1473-3099(22)00578-3
The paper
Carazo, S., Skowronski, D. M., Brisson, M., Barkati, S., Sauvageau, C., Brousseau, N., Gilca, R., Fafard, J., Talbot, D., Ouakki, M., Gilca, V., Carignan, A., Deceuninck, G., De Wals, P., & De Serres, G. (2023). Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(22)00578-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.